PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
28101677-1	2017	The MITO 15 was a prospective, single-arm trial, evaluating trabectedin monotherapy in patients with recurrent ovarian cancer (OC) who were BRCA mutation-carriers or had a BRCAness phenotype.	Trabectedin	60-71	BRCA1 DNA repair associated	Homo sapiens	140-144	
32365979-7	2020	In the group treated with trabectedin plus doxorubicin, the median of PFS was significantly longer in cases with CUL4A, ERCC1, or ERCC5 overexpression, while BRCA1 expression did not correlated with PFS.	Trabectedin	26-37	BRCA1 DNA repair associated	Homo sapiens	158-163	
28467918-2	2017	The tetrahydroisoquinolone trabectedin administered at 1.3 mg/m2 as a 3-h intravenous infusion every 3 weeks showed activity in patients with pretreated metastatic breast cancer (MBC) and BRCA germline mutations, but mainly in BRCA2 carriers.	Trabectedin	27-38	BRCA1 DNA repair associated	Homo sapiens	188-192	
15897246-8	2005	The transcriptional signature 72 hours after ET-743 administration, associated with ET-743 sensitivity, showed a more efficient induction of genes involved in DNA-damage response and apoptosis, such as RAD17, BRCA1, PAR4, CDKN1A, and P53DINP1, in the sensitive cell line group.	Trabectedin	45-51	BRCA1 DNA repair associated	Homo sapiens	209-214	
15897246-8	2005	The transcriptional signature 72 hours after ET-743 administration, associated with ET-743 sensitivity, showed a more efficient induction of genes involved in DNA-damage response and apoptosis, such as RAD17, BRCA1, PAR4, CDKN1A, and P53DINP1, in the sensitive cell line group.	Trabectedin	84-90	BRCA1 DNA repair associated	Homo sapiens	209-214